Cedelizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
  (what is this?) (verify) | |
Cedelizumab is a monoclonal antibody acting on the immune system.[1] Possible indications include the prevention of organ transplant rejections and the treatment of autoimmune diseases.[2]
It has been approved by both the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of patients with moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC).[3]
Vedolizumab is a humanized monoclonal antibody, which binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7) on T lymphocytes to interfere with lymphocyte trafficking to the gut.[3]
References
- ↑ WHO Drug Information
- ↑ The NDA pipeline. F-D-C Development Corporation. 2001.
- 1 2 Debnath P, Rathi PM (February 2021). "Vedolizumab in Inflammatory Bowel Disease: West versus East". Inflammatory Intestinal Diseases. 6 (1): 1–17. doi:10.1159/000512805. PMC 8015260. PMID 33850834.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.